Gilde Healthcare

We are pleased with the nomination of Real Deals ESG Awards 2024 as Impact Investor of the Year - Social. 🌟 This nomination underlines our dedication to impactful and responsible private equity investments. Investing in solutions for tomorrow's world! #GildeHealthcare #RDESGAwards #ImpactInvesting #SocialImpact #BetterCareatLowerCost

We are pleased to join the $150M financing round of CatalYm GmbH. CatalYm has identified GDF-15 as a key cancer therapy resistance mechanism and is now advancing to Phase 2b studies to confirm visugromab as a new class of cancer immunotherapy. #bettercareatlowercost #therapeutics #oncology #GDF-15 Phil L'Huillier Christine Schuberth-Wagner Eugen Leo Anne Burger Stefan Luzi, PhD Marion Pouillard Zosia van Eesteren Arthur Franken Besmire Ahmati Edwin de Graaf Geoff Pardo Joep Muijrers Pieter van der Meer Sonia Hallen Tristan Maguet Renee van der Ven

Portfolio company Eetgemak Groep becomes healthcare foodservice market leader with the acquisition of TotaalVERS   #PrivateEquity #Healthcare #Foodservice #Investments #bettercareatlowercost Hugo de Bruin Boyd Rutten Josephine Bogaerts Jelmer van der Ploeg Ludo Suykerbuyk Oksana van Vliet (Vynarchyk) Pieter van der Meer Besmire Ahmati Renee van der Ven Ronald Holtzer Jan-Pieter Ebben Gerard Hoetmer Tim de Vos Ronald van der Leer Martin van der Leer André van IJperen Onno Meijering Karlijn van der Hoeff Jaimy de Weijer RA Jody de Jong Jacoline Gortzak Eunice Bruyninckx Joyce Snijder Onno Hakvoort Oscar Janssen Ronald Braxhoofden Sander Thiadens Carlo De Haas Derk Hora Siccama Martijn Saillard Rick Voet Justin van Halst

Gilde Healthcare (#LSIEurope24 Investor) is a specialized healthcare investor managing over $2.6 billion across two fund strategies: Venture&Growth and Private Equity. The firm is headquartered in Utrecht, Netherlands with offices also in Frankfurt, Germany, and Boston, USA. In November of 2023, Gilde Healthcare announced the final close of its Gilde Healthcare Venture&Growth VI fund with €740 million in commitments. Fund VI reached the hard cap following a first close at €600 million in April 2023. The new fund focuses on fast-growing companies developing solutions for better care at lower costs. Gilde Healthcare invests in companies in Europe and North America active in digital healthcare, Medtech, and therapeutics. The new fund will invest €10-70 million per new portfolio company. The Venture&Growth fund portfolio includes companies like: • Argá Medtech SA (LSI Alumni - David Neale) • GT Medical Technologies, Inc. (LSI Alumni - Per Langoe) • Mainstay Medical (Jason Hannon) • Lumeon (Robbie Hughes) • Volta Medical (LSI Alumni - Théophile Mohr Durdez) We're excited to welcome Janke Dittmer, Susana Amorim Lopes, and Henry Zubaida from Gilde Healthcare to LSI Europe '24 this September in Sintra, Portugal. Want to see what other investors are joining us at LSI Europe ‘24? Head over to our website to see a preview of the 100 confirmed investors.

Congratulations to our portfolio company Volta Medical in presenting the positive outcome of the landmark TAILORED Atrial Fibrillation (AF) randomized controlled trial. Approximately 33 million patients worldwide are suffering from AF. Volta Medical’s artificial intelligence software solutions assist cardiac electrophysiologists during arrhythmia treatment procedures. #atrialfibrillation #healthtech #bettercareatlowercost Ariane Daney de Marcillac Arthur Franken Besmire Ahmati Christopher Allen Dirkjan B. Edward Hanlon Edwin de Graaf Geoff Pardo Henry Zubaida Janke Dittmer Joep Muijrers Karthik Bolisetty Marion Pouillard Pieter van der Meer Pommeline Korstanje Richard Wilmot Sonia Hallen Stefan Luzi, PhDi Susana Amorim Lopes Tristan Maguet Zosia van Eesteren

Gilde portfolio company KLIFO, which is a leading Northen European drug development consultancy and clinical trial supply business, has announced a double-digit million DKK investment to more than triple its Clinical Trial Supply (CTS) capacity in Denmark.

🎉 Wrapping up an inspiring first day at the 𝐓𝐞𝐜𝐡 𝐓𝐨𝐮𝐫 𝐌𝐞𝐧𝐭𝐚𝐥 & 𝐁𝐫𝐚𝐢𝐧 𝐇𝐞𝐚𝐥𝐭𝐡 Programme at Nova Business School in Carcavelos, Portugal! 🧠   34 of the most promising companies working in the field of mental & brain health were selected by a panel of 55 active investors to present their innovative solutions at the event. The participating investors have contributed in the past to over €35 Billion in total investments. 💡 It has been a day filled with enlightening pitching sessions, engaging keynotes, and dynamic panel discussions focused on investment trends in mental health, the possibilities of data and AI and ML, and scaling opportunities and challenges. 🤝 Networking was at the heart of the event, with one2one meetings designed to forge new partnerships and catalyze the growth of mental and brain health technologies. 🙌 𝐀 𝐡𝐞𝐚𝐫𝐭𝐟𝐞𝐥𝐭 𝐭𝐡𝐚𝐧𝐤 𝐲𝐨𝐮 A huge thank you to our host Nova School of Business and Economics, our partners Boehringer Ingelheim, Johnson & Johnson, Ontario Brain Institute, and Zest Scientific (division of Zest Business Group) and our supporting partners Baker Institute Center for Health and Biosciences, Behavioral Health Tech, Brain Innovation Days, Digital Health Today, European Brain Council, Frontiers Health, Galen Growth | Insights You Can Trust, Health Podcast Network, HealthXL, Healthware Group, MindAlliance Portugal, Unicorn Factory Lisboa and Leadership Marco Mohwinckel, Janke Dittmer, António Murta, Nuno Sousa A massive thank you to the President Marco Mohwinckel, our Programme Leaders António Murta and Nuno Sousa and the Selection Panel Vice President Janke Dittmer for their support throughout the whole Programme. ❗Stay tuned for the announcement of the best presenting companies. 🏆  #TechTour #TTMENTALHEALTH24 #MentalHealth #BrainHealth #HealthTech #Innovation #Investment #funding #startup #entrepreneur #founder #venturecapital #VC #healthplatforms #medicaldevices #biotechnology #wellness

We are pleased to act as a lead investor in the $100M financing round of diagnostic test provider Karius. The Karius Test improves the speed and comprehensiveness of diagnosis in the immunocompromised patient population by detecting over 1,000 pathogens, which fully aligns with our mission to improve patient care at lower cost. #bettercareatlowercost #diagnostics #infectiousdisease Ariane Daney de Marcillac Arthur Franken Besmire Ahmati Christopher Allen Dirkjan B. Edward Hanlon Edwin de Graaf Geoff Pardo Henry Zubaida Janke Dittmer Joep Muijrers Karthik Bolisetty Marion Pouillard Pieter van der Meer Pommeline Korstanje Richard Wilmot Sonia Hallen Stefan Luzi, PhD Susana Amorim Lopes Tristan Maguet Zosia van Eesteren

Join Geoff Pardo in his weekly medtech conversations with the innovators who are changing the landscape of medical technology to save patients and innovate healthcare for future generations. In this week’s episode, Geoff together with Conor Hanley, PhD, CEO of FIRE1 – a Gilde Healthcare Venture&Growth portfolio company, discuss among others entrepreneurship, and inclusive leadership.   Tune in for more via the below links: Spotify: https://lnkd.in/gHWa6E32 Apple Podcasts: https://lnkd.in/gjUTFBmH

Now at #InnovationDublin24 is the “Where to Find Late Stage and Growth Capital and how the Game is Played” panel session moderated by David Cassak of MedTech Strategist:   ●     Susana Amorim Lopes, Investment Manager, Gilde Healthcare ●     Olivier Litzka, Partner, Andera Partners ●     Ruben Osnabrugge, Partner, 415 Capital ●     Alexander Schmitz, Partner, Endeavour Vision Q: How does today’s dearth of early-stage capital shape later stage investing?   A. I haven’t lost confidence in the medtech space. 90% of M&A still happens in the commercial stage, so there is a need for late stage capital. "It was easy to raise money during COVID, but now the tourists have left. So now it comes back to fundamentals." "In terms of exits, medtech is much less predictable than biotech, with fewer buyers here, which also have veiled agendas." Remain informed on new articles, conference updates and more with our helpful medtech community newsletter. Subscribe here: https://bit.ly/42KHJKI